Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.

Encorafenib and binimetinib delivered to UK standard of care.